NSAIDs Vs. COX-2s: Study Prompts Labeling Review By FDA On Merck’s Vioxx
This article was originally published in The Tan Sheet
Executive Summary
OTC NSAID manufacturers may have been handed a significant marketing opportunity against COX-2s in the form of results from a retrospective study indicating the Rx pain relievers carry a higher risk of a serious cardiac event compared to their nonprescription counterparts
You may also be interested in...
Pfizer’s COX-2 Scripts Take More Hits From Kaiser
A decision by Kaiser Permanente physicians in California to stop prescribing Bextra demonstrates the challenges Pfizer must overcome as it seeks to reassure the public about the cardiovascular safety of COX-2 inhibitors
Celebrex Cardiovascular Safety Trial Will Allow Acetaminophen Use
Pfizer believes that allowing patients to take non-NSAID pain relievers, such as acetaminophen, in a trial evaluating the cardiovascular risk profile of Celebrex (celecoxib) will make a long-term placebo-controlled study in the arthritis population feasible
TARGET Study: Not Quite A Bull’s-Eye For COX-2 Inhibitors Over NSAIDs
Novartis' TARGET study found that the COX-2 inhibitor lumiracoxib has approximately one-third the rate of gastrointestinal side effects compared to prescription doses of non-steroidal anti-inflammatory drugs